A Phase II Evaluation of Gemcitabine (NSC 613327) and Docetaxel (NSC 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.

Trial Profile

A Phase II Evaluation of Gemcitabine (NSC 613327) and Docetaxel (NSC 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2010

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 13 Nov 2008 Status changed from suspended to active, no longer recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top